Ranitidine safety alert !

September 27, 2019

DCGI should have put the drug on temporary hold till it had been certified safe

India

healthysoch.com

New Delhi, September 27, 2019 :

Vide a notification F. No. 12-03/19/DC (Safety-007), the DCGI has issued a directive to all the States and UT Drug controllers regarding a nitrosamine impurity, N-nitrosodimethylamine (NDMA) in ranitidine.

Ranitidine is an OTC drug. It is also one of the most commonly prescribed drugs for heartburn and GERD.

The DCGI has asked all Drug controllers of states and UTs to communicate to the manufacturers of ranitidine API & formulations under their jurisdiction “to verify their products and take appropriate measures to ensure patient safety”.

As a precautionary measure, this is a welcome step. But, the safety alert issued by the office of DCGI is a serious matter. It shows that even the DCGI is concerned about this issue.

However, it should not have left it upon the states and UTs to take necessary action. Instead, the DCGI should have put a country-wide temporary hold on the drug till it had been certified safe.

In view of the current situation, all patients taking ranitidine should shift to or consider another group of acid blockers after discussing with their doctor. The most affordable alternative is omeprazole.

 

Author :Dr KK Aggarwal , Padma Shri Awardee

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Columnists

HealthySoch

Don't Miss

Morning MEDtalks with Dr K K Aggarwal

Around the globe : Morning MEDtalks with Dr K K Aggarwal

New Delhi, August 06, 2018 : Around the globe                                 Around

AstraZeneca strengthens innovation partnerships with NASSCOM – CoE IoT and Unnati to address Non-Communicable Diseases (NCDs) in India  

“Leif Johansson, Non-Executive Chairman of the Board, AstraZeneca PLC visits